XWPharma Announces Positive Results from Phase 1 Clinical Trials of XW10172, in Development as Once-Nightly Therapy for Sleep Disorders in Patients with Neurodegenerative Diseases

Phase 1 Results Demonstrate Optimal Pharmacokinetics, with Rapid Oral Absorption, Prompt Release of Oxybate from the New Chemical Entity XW10172, and Sustained Duration at Desired Plasma Concentrations Suitable for Once-Nightly DosingData Support Continued Development of XW10172; Phase 2 Trial in Sleep Disorders in Patients with Parkinson’s Disease is planned to start 3Q2021 followed by Single Registrational Trial in NarcolepsyResults Selected for Podium Presentation at SLEEP 2021, the Annual Meeting of the Associated Professional Sleep SocietiesREDWOOD CITY, CA and WUHAN, China, June 13, 2021 (GLOBE NEWSWIRE) – XWPharma Ltd. today announced that XW10172, an internally discovered, novel, patented conjugate of the GABAB agonist oxybate, demonstrated in Phase 1 clinical trials multiple features that support development for treatment for various sleep disorders. The results of these studies were presented by Daniel Canafax, PharmD, Chief Medical Officer of the company, in a podium presentation at virtual SLEEP 2021, the annual meeting of the Associated Professional Sleep Societies.

The release as fetched from its publisher. xwpharma.com ↗